Joana N. R. Dias

Dr. Joana N. R. Dias

CIISA - FMV-ULisboa
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2021 in Molecules
Verified
Journal Article
Open access
PDF file
MFMagda Ferreira
Magda Ferreira
MOMaria Ogren
Maria Ogren
Joana N. R. DiasJoana N. R. Dias
Joana N. R. Dias
MSMarta Silva
Marta Silva
Solange GilSolange Gil
Solange Gil
Sandra AguiarSandra Aguiar
Sandra Aguiar
Antimicrobial drugs are key tools to prevent and treat bacterial infections. Despite the early success of antibiotics, the current treatment of bacterial infections faces serious challenges due to the emergence and spread of resistant bacteria. Moreover, the decline of research and private investment in new antibiotics further aggravates this antibiotic crisis era. Overcoming the complexity of antimicrobial resistance must go beyond the search of new classes of antibiotics and include the development of alternative solutions. The evolution of nanomedicine has allowed the design of new drug delivery systems with improved therapeutic index for the incorporated compounds. One of the most promising strategies is their association to lipid-based delivery (nano)systems. A drug’s encapsulation in liposomes has been demonstrated to increase its accumulation at the infection site, minimizing drug toxicity and protecting the antibiotic from peripheral degradation. In addition, liposomes may be designed to fuse with bacterial cells, holding the potential to overcome antimicrobial resistance and biofilm formation and constituting a promising solution for the treatment of potential fatal multidrug-resistant bacterial infections, such as methicillin resistant Staphylococcus aureus. In this review, we aim to address the applicability of antibiotic encapsulated liposomes as an effective therapeutic strategy for bacterial infections.

Verified
Journal Article
Open access
PDF file
PBPedro Bule
Pedro Bule
Sandra AguiarSandra Aguiar
Sandra Aguiar
FSFrederico Aires Da Silva
Frederico Aires Da Silva
Joana N. R. DiasJoana N. R. Dias
Joana N. R. Dias
Chemokines are a large family of small chemotactic cytokines that coordinates immune cell trafficking. In cancer, they have a pivotal role in the migration pattern of immune cells into the tumor, thereby shaping the tumor microenvironment immune profile, often towards a pro-tumorigenic state. Furthermore, chemokines can directly target non-immune cells in the tumor microenvironment, including cancer, stromal and vascular endothelial cells. As such, chemokines participate in several cancer development processes such as angiogenesis, metastasis, cancer cell proliferation, stemness and invasiveness, and are therefore key determinants of disease progression, with a strong influence in patient prognosis and response to therapy. Due to their multifaceted role in the tumor immune response and tumor biology, the chemokine network has emerged as a potential immunotherapy target. Under the present review, we provide a general overview of chemokine effects on several tumoral processes, as well as a description of the currently available chemokine-directed therapies, highlighting their potential both as monotherapy or in combination with standard chemotherapy or other immunotherapies. Finally, we discuss the most critical challenges and prospects of developing targeted chemokines as therapeutic options.

Verified
Journal Article
Open access
PDF file
CCCatarina Fino Caseiro
Catarina Fino Caseiro
Joana N. R. DiasJoana N. R. Dias
Joana N. R. Dias
CFCarlos M. G. A. Fontes
Carlos M. G. A. Fontes
PBPedro Bule
Pedro Bule
β-glucans are a diverse group of polysaccharides composed of β-1,3 or β-(1,3-1,4) linked glucose monomers. They are mainly synthesized by fungi, plants, seaweed and bacteria, where they carry out structural, protective and energy storage roles. Because of their unique physicochemical properties, they have important applications in several industrial, biomedical and biotechnological processes. β-glucans are also major bioactive molecules with marked immunomodulatory and metabolic properties. As such, they have been the focus of many studies attesting to their ability to, among other roles, fight cancer, reduce the risk of cardiovascular diseases and control diabetes. The physicochemical and functional profiles of β-glucans are deeply influenced by their molecular structure. This structure governs β-glucan interaction with multiple β-glucan binding proteins, triggering myriad biological responses. It is then imperative to understand the structural properties of β-glucans to fully reveal their biological roles and potential applications. The deconstruction of β-glucans is a result of β-glucanase activity. In addition to being invaluable tools for the study of β-glucans, these enzymes have applications in numerous biotechnological and industrial processes, both alone and in conjunction with their natural substrates. Here, we review potential applications for β-glucans and β-glucanases, and explore how their functionalities are dictated by their structure.

2 October 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Sandra AguiarSandra Aguiar
Sandra Aguiar
Joana N. R. DiasJoana N. R. Dias
Joana N. R. Dias
AAAna André
Ana André
MSMarta Lisete Silva
Marta Lisete Silva
DMDiana Ferreira Martins
Diana Ferreira Martins
FSFrederico Aires Da Silva
Frederico Aires Da Silva
A major bottleneck in the successful development of central nervous system (CNS) drugs is the discovery and design of molecules that can cross the blood-brain barrier (BBB). Nano-delivery strategies are a promising approach that take advantage of natural portals of entry into the brain such as monoclonal antibodies (mAbs) targeting endogenous BBB receptors. However, the main selected mAbs rely on targeting broadly expressed receptors, such as the transferrin and insulin receptors, and in selection processes that do not fully mimic the native receptor conformation, leading to mistargeting and a low fraction of the administered dose effectively reaching the brain. Thus, there is an urgent need to identify new BBB receptors and explore novel antibody selection approaches that can allow a more selective delivery into the brain. Considering that in vitro models fail to completely mimic brain structure complexity, we explored an in vivo cell immunization approach to construct a rabbit derived single-domain antibody (sdAb) library towards BBB endothelial cell receptors. The sdAb antibody library was used in an in vivo phage display screening as a functional selection of novel BBB targeting antibodies. Following three rounds of selections, next generation sequencing analysis, in vitro brain endothelial barrier (BEB) model screenings and in vivo biodistribution studies, five potential sdAbs were identified, three of which reaching >0.6% ID/g in the brain. To validate the brain drug delivery proof-of-concept, the most promising sdAb, namely RG3, was conjugated at the surface of liposomes encapsulated with a model drug, the pan-histone deacetylase inhibitor panobinostat (PAN). The translocation efficiency and activity of the conjugate liposome was determined in a dual functional in vitro BEB-glioblastoma model. The RG3 conjugated PAN liposomes enabled an efficient BEB translocation and presented a potent antitumoral activity against LN229 glioblastoma cells without influencing BEB integrity. In conclusion, our in vivo screening approach allowed the selection of highly specific nano-antibody scaffolds with promising properties for brain targeting and drug delivery.

19 June 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
Joana N. R. DiasJoana N. R. Dias
Joana N. R. Dias
Sandra AguiarSandra Aguiar
Sandra Aguiar
DPDiane M. Pereira
Diane M. Pereira
AAAna André
Ana André
Lurdes GanoLurdes Gano
Lurdes Gano
FSFrederico Aires Da Silva
Frederico Aires Da Silva
The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma

1 January 2018
Verified
Book Chapter
Closed access
Sandra AguiarSandra Aguiar
Sandra Aguiar
Joana N. R. DiasJoana N. R. Dias
Joana N. R. Dias
AMAna M. Manuel
Ana M. Manuel
RRRoberto Russo
Roberto Russo
PGPedro M. P. Gois
Pedro M. P. Gois
João GonçalvesJoão Gonçalves
João Gonçalves